Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Sorafenib, Oxaliplatin, and S-1 for HCC Recurrence After Liver Transplant
NCT02129322Phase 2Withdrawn
- Sponsor
- Zhejiang University
- Start
- Jul 2015
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tegafur in hepatocellular carcinoma (HCC), sponsored by Zhejiang University. Planned start Jul 2015; status: withdrawn.
02
Drugs
tegafur
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02129322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02129322.